Vir Biotechnology Inc. (VIR) Prices 7.14M Share Common Offering at $42/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vir Biotechnology Inc. (VIR) Names Elliott Sigal, M.D., Ph.D. to Board
July 10, 2020 4:03 PM EDTVir Biotechnology, Inc. (NASDAQ: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristol-Myers Squibb Company (BMS) Research and Development (R&D), where he played an instrumental role in bringing 14 new medicines to patients in need.
The Vir team is excited to welcome such an accomplished leader to our board of directors, said George Scangos, Ph.D., chief executive officer of Vir. Bringing more than 25 years of invaluable experience in... More
Vir Biotechnology Inc. (VIR) Announces Proposed Public Offering of Common Stock
July 6, 2020 7:03 AM EDTVir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to... More
